Capstone Therapeutics Stock (NASDAQ:CAPS)
Previous Close
$1.56
52W Range
$1.30 - $16.18
50D Avg
$1.75
200D Avg
$2.47
Market Cap
$9.24M
Avg Vol (3M)
$429.31K
Beta
-0.82
Div Yield
-
CAPS Company Profile
Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.